These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29983344)

  • 1. Enzalutamide and metastasis risk in prostate cancer.
    Gourd E
    Lancet Oncol; 2018 Aug; 19(8):e387. PubMed ID: 29983344
    [No Abstract]   [Full Text] [Related]  

  • 2. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
    Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
    Arslan C
    World J Urol; 2017 Mar; 35(3):479-480. PubMed ID: 27417948
    [No Abstract]   [Full Text] [Related]  

  • 4. Enzalutamide shows strong activity in prostate cancer.
    Cancer Discov; 2014 Apr; 4(4):OF2. PubMed ID: 24706671
    [No Abstract]   [Full Text] [Related]  

  • 5. [Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].
    Boegemann M
    Urologe A; 2020 Jan; 59(1):78-79. PubMed ID: 31853892
    [No Abstract]   [Full Text] [Related]  

  • 6. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
    Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
    BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
    Tombal B
    Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
    Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H
    Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
    J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer.
    Rhea LP; Gupta B; Aragon-Ching JB
    Asian J Androl; 2019; 21(2):107-108. PubMed ID: 30460933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.
    Graff JN; Gordon MJ; Beer TM
    Expert Opin Pharmacother; 2015 Apr; 16(5):749-54. PubMed ID: 25687355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
    J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
    Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prostate cancer - enzalutamide extends survival].
    Aktuelle Urol; 2014 Mar; 45(2):98. PubMed ID: 24818263
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide.
    Baciarello G; Sternberg CN
    Crit Rev Oncol Hematol; 2016 Oct; 106():14-24. PubMed ID: 27637350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is in vitro-acquired resistance to enzalutamide a useful model?
    Buonerba C; Di Lorenzo G
    Future Oncol; 2014 Dec; 10(16):2551-3. PubMed ID: 25531044
    [No Abstract]   [Full Text] [Related]  

  • 18. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.
    Sternberg CN; de Bono JS; Chi KN; Fizazi K; Mulders P; Cerbone L; Hirmand M; Forer D; Scher HI
    Ann Oncol; 2014 Feb; 25(2):429-34. PubMed ID: 24478320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
    Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO
    Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.